Back to News
Market Impact: 0.32
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
Source: zacks.com
Corporate EarningsHealthcare & BiotechAnalyst Estimates
AnaptysBio reported a quarterly loss of $0.11 per share, substantially narrower than the Zacks consensus forecast for a $0.46 loss. The result also improved sharply from a $1.34-per-share loss in the prior-year quarter, indicating a $1.23 year-over-year reduction in losses.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
ANAB0.72
More News
- Perpetual underdog AMD nips at Nvidia's heels as it joins the $1T club
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
- Chip stocks snap back on multi-billion-dollar AI bet - AI Strategy got in early
- Ra Capital Management sells $21.8m in Sionna Therapeutics shares
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- Why is Labcorp stock sliding today?